MASSACHUSETTS GENERAL HOSPITAL

TPN-101, a first-in-class LINE-1 reverse transcriptase inhibitor, has been selected for inclusion in the Phase 2/3 HEALEY ALS Platform Trial based on promising Phase 2 data.

Mythic Therapeutics will present updated dose escalation data from its Phase 1 KisMET-01 study of MYTX-011, a cMET-targeting antibody-drug conjugate, at the 2025 ASCO Annual Meeting.

Hillhurst Biopharmaceuticals has received $6.3 million in grants, including $2 million from The Michael J. Fox Foundation and $4.3 million from the Farmer Family Foundation in collaboration with Massachusetts General Hospital.

Massachusetts General Hospital has enrolled the first patient in a trial evaluating RELiZORB's efficacy in managing exocrine pancreatic insufficiency in tube-fed pancreatitis patients.

A groundbreaking clinical trial reveals varenicline combined with remote behavioral counseling achieved 51% vaping abstinence rates in youth compared to 14% with placebo during the final four weeks of treatment.

New research shows that complete blood count (CBC) tests can identify or predict multiple diseases including heart problems, type 2 diabetes, osteoporosis, and kidney disease by analyzing individual "set points" in blood components.

Researchers have developed a portable AI system that analyzes motor function to detect mild cognitive impairment with 83% accuracy, potentially enabling earlier intervention for dementia and Alzheimer's disease.

New research reveals that more than 10.6 hours of daily sedentary behavior significantly increases risk of heart failure and cardiovascular mortality, even among those meeting exercise guidelines.

Real-world data presented at AUA 2025 shows the CVAC System achieves significant kidney stone volume reduction of up to 99% in most patients, with one study reporting a median clearance rate of 96.4%.

CytoSite Bio has signed a collaboration agreement with Lantheus Holdings for the clinical development and commercialization of a Phase 1-ready granzyme B-targeted PET imaging radiotracer.